163 related articles for article (PubMed ID: 37974946)
1. Peptide-to-Small Molecule: Discovery of Non-Covalent, Active-Site Inhibitors of β-Herpesvirus Proteases.
Yoshida S; Sako Y; Nikaido E; Ueda T; Kozono I; Ichihashi Y; Nakahashi A; Onishi M; Yamatsu Y; Kato T; Nishikawa J; Tachibana Y
ACS Med Chem Lett; 2023 Nov; 14(11):1558-1566. PubMed ID: 37974946
[TBL] [Abstract][Full Text] [Related]
2. Peptide-to-Small Molecule: A Pharmacophore-Guided Small Molecule Lead Generation Strategy from High-Affinity Macrocyclic Peptides.
Yoshida S; Uehara S; Kondo N; Takahashi Y; Yamamoto S; Kameda A; Kawagoe S; Inoue N; Yamada M; Yoshimura N; Tachibana Y
J Med Chem; 2022 Aug; 65(15):10655-10673. PubMed ID: 35904556
[TBL] [Abstract][Full Text] [Related]
3. The herpesvirus proteases as targets for antiviral chemotherapy.
Waxman L; Darke PL
Antivir Chem Chemother; 2000 Jan; 11(1):1-22. PubMed ID: 10693650
[TBL] [Abstract][Full Text] [Related]
4. The herpesvirus protease: mechanistic studies and discovery of inhibitors of the human cytomegalovirus protease.
Flynn DL; Becker DP; Dilworth VM; Highkin MK; Hippenmeyer PJ; Houseman KA; Levine LM; Li M; Moormann AE; Rankin A; Toth MV; Villamil CI; Wittwer AJ; Holwerda BC
Drug Des Discov; 1997 May; 15(1):3-15. PubMed ID: 9332827
[TBL] [Abstract][Full Text] [Related]
5. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
Awoonor-Williams E
Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
[TBL] [Abstract][Full Text] [Related]
6. Antiviral Drug Discovery: Norovirus Proteases and Development of Inhibitors.
Chang KO; Kim Y; Lovell S; Rathnayake AD; Groutas WC
Viruses; 2019 Feb; 11(2):. PubMed ID: 30823509
[TBL] [Abstract][Full Text] [Related]
7. Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease.
Choudhury C
J Biomol Struct Dyn; 2021 Jul; 39(10):3733-3746. PubMed ID: 32452282
[TBL] [Abstract][Full Text] [Related]
8. Selective nonpeptidic inhibitors of herpes simplex virus type 1 and human cytomegalovirus proteases.
Matsumoto M; Misawa S; Chiba N; Takaku H; Hayashi H
Biol Pharm Bull; 2001 Mar; 24(3):236-41. PubMed ID: 11256477
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
Gao S; Song L; Claff T; Woodson M; Sylvester K; Jing L; Weiße RH; Cheng Y; Sträter N; Schäkel L; Gütschow M; Ye B; Yang M; Zhang T; Kang D; Toth K; Tavis J; Tollefson AE; Müller CE; Zhan P; Liu X
J Med Chem; 2022 Dec; 65(24):16902-16917. PubMed ID: 36475694
[TBL] [Abstract][Full Text] [Related]
10. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
Hajbabaie R; Harper MT; Rahman T
Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
[TBL] [Abstract][Full Text] [Related]
11. Conformational selection of inhibitors and substrates by proteolytic enzymes: implications for drug design and polypeptide processing.
Fairlie DP; Tyndall JD; Reid RC; Wong AK; Abbenante G; Scanlon MJ; March DR; Bergman DA; Chai CL; Burkett BA
J Med Chem; 2000 Apr; 43(7):1271-81. PubMed ID: 10753465
[TBL] [Abstract][Full Text] [Related]
12. From 1-acyl-beta-lactam human cytomegalovirus protease inhibitors to 1-benzyloxycarbonylazetidines with improved antiviral activity. A straightforward approach to convert covalent to noncovalent inhibitors.
Gerona-Navarro G; Pérez de Vega MJ; García-López MT; Andrei G; Snoeck R; De Clercq E; Balzarini J; González-Muñiz R
J Med Chem; 2005 Apr; 48(7):2612-21. PubMed ID: 15801851
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Covalently Binding Warhead Compounds in the Validation of the Cytomegalovirus Nuclear Egress Complex as an Antiviral Target.
Tillmanns J; Häge S; Borst EM; Wardin J; Eickhoff J; Klebl B; Wagner S; Wangen C; Hahn F; Socher E; Marschall M
Cells; 2023 Apr; 12(8):. PubMed ID: 37190072
[TBL] [Abstract][Full Text] [Related]
14. Novel covalent and non-covalent complex-based pharmacophore models of SARS-CoV-2 main protease (M
Hayek-Orduz Y; Vásquez AF; Villegas-Torres MF; Caicedo PA; Achenie LEK; González Barrios AF
Sci Rep; 2022 Aug; 12(1):14030. PubMed ID: 35982147
[TBL] [Abstract][Full Text] [Related]
15. Fragment-Based Protein-Protein Interaction Antagonists of a Viral Dimeric Protease.
Gable JE; Lee GM; Acker TM; Hulce KR; Gonzalez ER; Schweigler P; Melkko S; Farady CJ; Craik CS
ChemMedChem; 2016 Apr; 11(8):862-9. PubMed ID: 26822284
[TBL] [Abstract][Full Text] [Related]
16. Discovery of antiviral SARS-CoV-2 main protease inhibitors by structure-guided hit-to-lead optimization of carmofur.
Kang KM; Jang Y; Lee SS; Jin MS; Jun CD; Kim M; Kim YC
Eur J Med Chem; 2023 Nov; 260():115720. PubMed ID: 37633203
[TBL] [Abstract][Full Text] [Related]
17. Development of a Novel Pharmacophore Model Guided by the Ensemble of Waters and Small Molecule Fragments Bound to SARS-CoV-2 Main Protease.
Kumar P; Mohanty D
Mol Inform; 2022 Feb; 41(2):e2100178. PubMed ID: 34633768
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.
Yu W; Zhao Y; Ye H; Wu N; Liao Y; Chen N; Li Z; Wan N; Hao H; Yan H; Xiao Y; Lai M
J Med Chem; 2022 Dec; 65(24):16252-16267. PubMed ID: 36503248
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional structure of human cytomegalovirus protease.
Shieh HS; Kurumbail RG; Stevens AM; Stegeman RA; Sturman EJ; Pak JY; Wittwer AJ; Palmier MO; Wiegand RC; Holwerda BC; Stallings WC
Nature; 1996 Sep; 383(6597):279-82. PubMed ID: 8805708
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
